A study from Zhejiang University School of Medicine and collaborating institutions reveals that the protein TAF1 acts as a context-dependent switch for ferroptosis, with its effect hinging entirely on the status of the TP53 gene.
The Context-Dependent Role of TAF1 in Ferroptosis
Researchers from Zhejiang University School of Medicine, Zhejiang Cancer Hospital, Taizhou Hospital of Zhejiang Province, and Peking Union Medical College Hospital have published a pivotal study in the Journal of Zhejiang University-SCIENCE B (DOI: 10.1631/jzus.B2500567, 2026). The investigation reveals that TATA box-binding protein-associated factor 1 (TAF1) regulates ferroptosis through fundamentally different mechanisms depending on the TP53 status of the cell.
Methods: Uncovering the Dual Mechanism
- The team screened pan-cancer datasets, identifying TAF1 as a protein consistently linked to reduced expression of ferroptosis suppressors.
- To probe this relationship, they conducted experiments using TAF1-knockout colorectal and ovarian cancer cell lines, treating them with the GPX4 inhibitor RSL3 to induce ferroptosis.
Key Findings: A Bipolar Switch
The results reveal a stark duality in TAF1's function:
- In TP53-mutant or TP53-null cells: TAF1 knockout reduced ferroptosis sensitivity.
- In TP53-wild-type cells: TAF1 knockout increased ferroptosis sensitivity.
Mechanism 1: The TP53-Mutant Pathway
In TP53-mutant cells, TAF1 interacts with nuclear GPX4 (nGPX4) and promotes K11-linked ubiquitination. This targets nGPX4 for proteasomal degradation, which decreases antioxidant protection and increases ferroptosis susceptibility.
Mechanism 2: The TP53-Wild-Type Pathway
In TP53-wild-type cells, TAF1 promotes MDM2-mediated TP53 degradation. This leads to increased expression of the ferroptosis suppressor SLC7A11, ultimately reducing ferroptosis sensitivity.
In Vivo Validation
Mouse xenograft experiments using SW620 cells (which are TP53-mutant) confirmed that TAF1 enhances ferroptosis in TP53-mutant tumors.
Implications for Therapy
This study fundamentally alters the understanding of ferroptosis regulation, showing it is not a unidirectional process. TAF1 acts as a context-sensitive switch that integrates TP53 status to determine cellular vulnerability to ferroptosis.
The findings suggest a clear, testable hypothesis for clinical application: TP53 status may predict tumor response to ferroptosis-inducing therapies.
- TP53-mutant tumors with high TAF1 expression may be more responsive to ferroptosis inducers.
- TP53-wild-type tumors with low TAF1 expression may also be sensitive.
Furthermore, the discovery that nGPX4 degradation via ubiquitin-mediated pathways emerges as a potential therapeutic target opens a new avenue for drug development.
Source: Ye, K., et al. (2026), Journal of Zhejiang University-SCIENCE B, DOI: 10.1631/jzus.B2500567.